Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Silence Therapeutics (SLN) Other Non Operating Income (2020 - 2025)

Silence Therapeutics' Other Non Operating Income history spans 6 years, with the latest figure at $880000.0 for Q4 2025.

  • On a quarterly basis, Other Non Operating Income rose 131.61% to $880000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.8 million, a 77.32% increase, with the full-year FY2025 number at $3.5 million, up 438.7% from a year prior.
  • Other Non Operating Income hit $880000.0 in Q4 2025 for Silence Therapeutics, down from $1.9 million in the prior quarter.
  • Over the last five years, Other Non Operating Income for SLN hit a ceiling of $357.1 million in Q1 2021 and a floor of -$11.4 million in Q3 2024.
  • Historically, Other Non Operating Income has averaged $16.8 million across 5 years, with a median of -$64150.0 in 2021.
  • The widest YoY moves for Other Non Operating Income: up 243.77% in 2024, down 112358.92% in 2024.
  • Tracing SLN's Other Non Operating Income over 5 years: stood at -$295214.3 in 2021, then crashed by 92.7% to -$568870.2 in 2022, then crashed by 587.04% to -$3.9 million in 2023, then grew by 28.77% to -$2.8 million in 2024, then skyrocketed by 131.61% to $880000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for SLN at $880000.0 in Q4 2025, $1.9 million in Q3 2025, and -$6.6 million in Q2 2025.